CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study

    NEXT STORY
    Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual Assembly
    PREV STORY
    Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Algernon Pharmaceuticals Appoints Dr. Mark Swaim MD, PhD to its Medical and Scientific Advisory Board

    author_avatar
    NASDAQ Market News

    Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational Results

    author_avatar
    NASDAQ Market News

    Global IV and Oral Iron Drugs Markets 2019-2024 – Investigational Iron Drugs and Expected Approvals in Newer Markets

    author_avatar
    NASDAQ Market News